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ABSTRACT
The authors report a case of
treatment-resistant schizophrenia in
a 22-year-old woman, who, despite
multiple trials of antipsychotics, did
not respond to treatment. Clozapine
treatment was initiated, but the
patient’s symptoms did not remit
until after she had a clozapineinduced seizure. The authors discuss
the importance in considering that
electroconvulsive therapy may be
effective in reducing positive and
negative symptoms in patients
suffering from treatment-resistant
schizophrenia.

INTRODUCTION
The diagnosis of treatmentresistant schizophrenia (TRS) is
made after failure of multiple
optimum medication trials.
Clozapine, a dibenzodiazepine
atypical anti-psychotic, is a drug of
choice for TRS. However, its side
effects, including sialorrohea,
constipation, sedation, orthostatic
hypotension, chest pain, nocturnal
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enuresis, and increased risk of
seizures, pose a major hindrance to
its use.1 Paradoxically, there is
evidence that seizures (including
electroconvulsive therapy [ECT])
improve the symptoms of
schizophrenia.2
Here, we present the case of a 22year-old woman who suffered from
schizophrenia for the previous 1.5
years. Despite multiple trials of
antipsychotics, she did not respond
to treatment. Her symptoms as well
as her functionality continued to
deteriorate, which required the
initiation of clozapine in an attempt
to control her symptoms. In an inpatient setting, she suffered a
seizure, which was believed to be
caused by the clozapine. Immediately
following the seizure and after
reducing the clozapine dosage and
adding divalproex sodium, her
symptoms remitted and baseline
functionality returned.
We discuss the importance of
considering ECT in patients suffering
from TRS.

CASE REPORT
Ms. U was 22-year-old single
woman diagnosed with TRS. The
prominent symptoms included
auditory hallucinations, self-talking,
and self-laughing, mumbling,
gesturing, and thought block, which
led to a preoccupied mental state.
She was prescribed risperidone
initially, which was titrated to 6mg.
When no response was seen after the
use of this medication for an
optimum period of six weeks,
olanzapine 5mg was added and the
dose was titrated up to 20mg. The
patient was observed for the next six
weeks, but did not show any
improvement. Her main symptoms
were muteness, aggression,
persecutory delusions, and auditory
hallucinations, which continued to
worsen. She was admitted for reevaluation, and basic investigations
were conducted. As she was now
considered treatment resistant, the
option of clozapine was discussed
and initiated, and the dose was
titrated up as per in-patient protocol
(according to Maudsley Prescribing
Guidelines).3 She was observed for
side effects and manifested
sialorrhoea and sedation after one
week. These symptoms were
managed with trihexyphenidyl HCl
(2mg) and shifting the night dose of
clozapine to the morning.
On the 14th day of clozapine
treatment, the patient’s 175mg
dosage was divided into 75mg in
morning and 100mg in evening. That
day, the patient had an unobserved
fall in the bathroom that caused an
injury to her head with bleeding and
development of myoclonic jerks.
Emergency services were called, and
the patient was administered
2,000mg of divalproex sodium
intravenously, during which she had
a generalized tonic-clonic seizure.
The seizure was aborted through the
administration of 5mg midazolam
intravenously. The neurology team
was consulted, and a computerized
tomography (CT) scan without
contrast and an
electroencephalogram (EEG) were
ordered and performed. The CT scan

was unremarkable, and the EEG
showed a generalized temporal
dominant burst of slow waves and
slow dominant rhythm. The patient
regained consciousness after 10
minutes and became alert after a few
more minutes, at which time oral
divalproex sodium was initiated. The
next day, it was observed that the
patient’s mental state had drastically
improved. No preoccupation, thought
block, or persecutory delusions were
observed, and the patient denied any
other psychotic symptoms. She
started interacting with her family.
According to her mother, her
interaction was similar to her
previous healthy baseline pattern.
This state continued until
discharge, which was five days after
the seizure. Immediately following
the seizure, clozapine was initially
discontinued for a day, but then was
restarted at 25mg with a plan of
gradual dosage increase and
continued administration of
divalproex sodium.
At the time of discharge, the
patient was on divalproex sodium
500mg and clozapine 25mg at night.
One week later during the follow-up
visit, her mother reported increased
sedation for most of the day, along
with complaints of alopecia and
increased appetite; however, no
positive or negative symptoms of
schizophrenia were reported at that
time. The patient’s mother advised
the patient to use herbal and
alternative medicine strategies to
manage her hair loss and weight
gain. Her mother expressed social
concerns regarding stigma, marriage,
and social disposition of her daughter
in the long run; however, the patient
was able to participate in daily social
interactions and pursue her future
plans regarding career and interests.

DISCUSSION
Improvement in our patient’s
mental state was very drastic and
very closely temporally associated
with the occurrence of the seizure.
Clozapine-induced seizures are
known to occur, as clozapine
decreases the seizure threshold, and
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the cumulative one-year risk of
seizure is about five percent.4 In our
patient, the dose of clozapine was
high and there was no other
comorbid medical or neurological
condition that could explain the
seizure, leading us to the conclusion
that the seizure was caused by
clozapine.
ECT has been effective in
improving patients on clozapine, and
as ECT is based on the mechanism
of seizure production, we postulate
that the “natural” ECT our patient
experienced therapeutically
augmented the clozapine and
resulted symptom remission.5 In a
study conducted in Iran that
investigated use of clozapine with
ECR, patients with TRS were split
into three treatment groups: those
administered clozapine with no ECT
(46% remission rate), those
administered ECT with no clozapine
(40%), and those administered ECT
with clozapine (71%). Using the
PANSS scale, investigators found
that the concurrent effect of
clozapine and ECT resulted in
substantial improvement of TRS
symptoms, and suggested that this
treatment combination is a safe and
effective approach to managing
TRS.6,7 It has also been shown that
ECT does not cause epilepsy; rather,
it increases the seizure threshold
and is also helpful in managing
breakthrough seizures—thus helping
control clozapine-induced seizures
as well.8
The management of patients with
schizophrenia who do not respond to
clozapine can be difficult, and polypharmacy is indicated in this group,9
which has its own limitations due to
side effects and drug interactions.
Before discontinuing clozapine in
these patients due to
ineffectiveness, clinicians may
consider using ECT on these
patients in addition to the
administration of clozapine.
However, more rigorous data are
needed to prove the benefit of ECT
in this patient population before this
combination is included in evidencebased guidelines for treating TRS.
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SUMMARY
In cases of TRS with failed trials
of clozapine, ECT may prove
efficacious when used in combination
with the drug. In our patient, a
seizure secondary to clozapine
appeared to have augmented the
effect of the medication. Symptom
reduction in patients with TRS using
ECT should undergo further
investigative studies to determine
the full extent of impact that
seizures may have in reducing
psychotic symptoms.

2.

ACKNOWLEDGMENT

5.

3.

4.

The authors wish to thank Waliyah
Mughis for her editorial assistance in
the preparation of this manuscript.

REFERENCES
1.

80

Young CR, Bowers MB, Mazure CM.
Management of the adverse effects
of clozapine. Schiz Bull.

Innovations in CLINICAL NEUROSCIENCE

6.

1998;24(3):381–390.
Pompili M, Lester D, Dominici G, et
al. Indications for electroconvulsive
treatment in schizophrenia: a
systematic review. Schiz Res.
2013;146(1):1–9.
Williams AM, Park SH. Seizure
associated with olozapine:
incidence, etiology, and
management. CNS Drugs.
2015;29(2):101–111
Taylor D, Paton C, Kapur S. The
Maudsley Prescribing Guidelines
in Psychiatry. Hoboken, NJ: John
Wiley & Sons; 2015.
Park S, Lee M. Successful
electroconvulsive therapy and
improvement of negative
symptoms in refractory
schizophrenia with clozapineinduced seizures: a case report.
Psychiatria Danubina.
2014;26(4):360–362.
Masoudzadeh A, Khalilian AR.

[VOLUME 13, NUMBER 5–6, MAY–JUNE 2016]

7.

8.

9.

Comparative study of clozapine,
electroshock, and the combination
of ECT with clozapine in
treatment-resistant schizophrenic
patients. Pakistan J Biologic Sci.
2007;10(23):4287–4290.
Bhatia SC, Bhatia SK, Gupta S.
Concurrent administration of
clozapine and ECT: a successful
therapeutic strategy for a patient
with treatment-resistant
schizophrenia. J ECT. 1998;14(4).
Sackeim H, Decina P, Prohovnik I,
Malitz S. Seizure threshold in
electroconvulsive therapy: effects
of sex, age, electrode placement,
and number of treatments. JAMA.
1987;44(4).
Zink M, Henn FA, Thome J.
Combination of amisulpride and
olanzapine in treatment-resistant
schizophrenic psychoses. Eur
Psychiatry. 2004;19(1):56–58.

